TEVA-MEDROXYPROGESTERONE TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
26-02-2015
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
MEDROXYPROGESTERONE ACETATE
Tilgjengelig fra:
TEVA CANADA LIMITED
ATC-kode:
G03DA02
INN (International Name):
MEDROXYPROGESTERONE
Dosering :
10MG
Legemiddelform:
TABLET
Sammensetning:
MEDROXYPROGESTERONE ACETATE 10MG
Administreringsrute:
ORAL
Enheter i pakken:
100/500/1000
Resept typen:
Prescription
Terapeutisk område:
PROGESTINS
Produkt oppsummering:
Active ingredient group (AIG) number: 0106339006; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2011-01-18
Preparatomtale
PRODUCT MONOGRAPH
PR
TEVA-MEDROXYPROGESTERONE
medroxyprogesterone acetate tablets USP
2.5 mg, 5 mg and 10 mg
PROGESTIN
Teva Canada Limited
Date of Revision:
30 Novopharm Court
May 12, 2014
Toronto, Ontario
M1B 2K9
Control No: 173232
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
..........................................................................................................
16
DOSAGE AND ADMINISTRATION
......................................................................................
18
OVERDOSAGE
........................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
21
STORAGE AND STABILITY
.................................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.................................................................................
25
CLINICAL
TRIALS..................................................................................................................
26
DETAILED PHARMACOLOGY
.............................................................................................
28
TOXICOLOGY
..............
Les hele dokumentet
